GARY PATOU - 05 Jun 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
05 Jun 2025
Net transactions value
$0
Form type
4
Filing time
06 Jun 2025, 18:00:25 UTC
Previous filing
22 Nov 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PATOU GARY Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 06 Jun 2025 0001283535

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +17,012 $0.000000 17,012 05 Jun 2025 Common Shares 17,012 $30.73 Direct F1
transaction XENE Restricted Share Units Award $0 +2,645 $0.000000 2,645 05 Jun 2025 Common Shares 2,645 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.